Provider briefing: Synvisc access challenges in 2026

As healthcare providers, you're likely fielding increasing patient questions about Synvisc availability. While there's no actual manufacturing shortage, the complex dynamics around specialty medication access are creating real challenges for both practices and patients.

This briefing provides you with current information to help navigate Synvisc prescribing decisions and manage patient expectations effectively.

Current supply status: the facts

Manufacturing status: Sanofi confirms normal production levels for both Synvisc and Synvisc-One. There are no FDA-reported shortages or manufacturing disruptions as of March 2026.

Distribution challenges: The issue isn't supply—it's the economics and logistics of specialty medication distribution:

• High per-unit costs ($600-$1,200 per vial) strain practice cash flow
• Limited shelf life creates inventory risk
• Storage requirements (2-8°C) require dedicated space
• Prior authorization unpredictability affects demand forecasting

Regional variations: Access varies significantly by geographic area, with urban academic centers typically maintaining better availability than smaller community practices.

Timeline of recent developments

2023-2024: Post-COVID practice consolidation led many smaller orthopedic and rheumatology practices to streamline specialty medication inventory.

2024-2025: Insurance companies implemented stricter prior authorization requirements, increasing administrative burden and approval timeframes.

2026 current: While supply is stable, access patterns have fundamentally shifted toward larger practices and specialty pharmacy partnerships.

Prescribing implications for your practice

Patient counseling considerations

When prescribing Synvisc, set appropriate expectations:

• Timeline: Allow 2-4 weeks from prescription to injection (includes PA processing and medication sourcing)
• Alternatives: Discuss backup options during initial consultation
• Cost transparency: Review expected out-of-pocket costs upfront
• Access challenges: Explain why it may not be available immediately

Prior authorization best practices

Current PA requirements typically include:

• Documentation of failed conservative therapy (6+ weeks of PT, NSAIDs, activity modification)
• Failed corticosteroid injection (within 6 months)
• Radiographic evidence of moderate osteoarthritis
• Functional assessment scores (WOMAC, KOOS)

Pro tip: Submit comprehensive documentation initially. Incomplete PAs are the leading cause of delays and denials.

Current availability landscape

Practice types with reliable access

• Academic medical centers: Higher patient volume justifies inventory investment
• Large orthopedic groups: Can absorb inventory costs across multiple providers
• ASCs with joint programs: Dedicated arthritis centers maintain comprehensive options
• Specialty pharmacy partnerships: Direct-delivery models ensure availability

Inventory management strategies

For practices considering stocking:

• Calculate break-even patient volume (typically 8-12 patients annually)
• Negotiate with distributors for consignment arrangements
• Consider patient pre-payment for high-cost inventory
• Implement first-expiry-first-out rotation protocols

Alternative approach—order on demand:

• Partner with specialty pharmacy for direct delivery
• Order only after confirmed PA approval
• Schedule injections 1-2 weeks after order placement
• Maintain relationships with multiple distributors

Insurance coverage and reimbursement updates

2026 payer landscape

Medicare: Continues coverage under DME benefit when LCD criteria met. Average reimbursement: $400-$600 per injection.

Commercial plans: Coverage varies significantly:

• Tier 1 preferred: Euflexxa, Hyalgan (lower PA barriers)
• Tier 2 covered: Synvisc, Orthovisc (standard PA required)
• Tier 3 non-preferred: Some plans exclude viscosupplements entirely

Prior authorization trends:

• Step therapy requirements increasing (must fail 2+ conservative treatments)
• Some plans require rheumatology or orthopedic specialist referral
• Documentation requirements becoming more stringent

Reimbursement optimization

• J-code billing: Use appropriate J-codes (J7325 for Synvisc, J7326 for Synvisc-One)
• Administration coding: Bill injection procedure separately (20610)
• Documentation requirements: Support medical necessity with functional assessments
• Appeals process: Maintain template letters for common denials

Alternative prescribing options

When Synvisc isn't accessible

First-line alternatives:

• Hyalgan: Often better insurance coverage, 5-injection series
• Euflexxa: Non-avian source, good for allergy concerns, 3-injection series
• Orthovisc: Similar efficacy profile, often more readily available

Single-injection options:

• Gel-One: Cost-effective single treatment
• Monovisc: Extended duration claims
• Durolane: Non-avian, single injection

Evidence-based selection criteria

Research shows comparable efficacy across viscosupplements. Selection factors:

• Patient preference: Single vs. multiple injections
• Insurance coverage: Check formulary preferences
• Practice availability: Stock what you can access reliably
• Allergy history: Avian vs. bacterial-derived options

Tools and resources for providers

Patient navigation resources

• Medfinder platform: medfinder.com/providers helps patients locate practices with availability
• Manufacturer resources: Sanofi provides practice locator and PA support
• Specialty pharmacy partnerships: Direct delivery coordination services

Practice efficiency tools

• PA templates: Standardized documentation for common scenarios
• Patient education materials: Explain treatment options and timelines
• Inventory tracking: Monitor usage patterns and expiration dates
• Alternative protocols: Decision trees for when preferred options aren't available

Looking ahead: strategic considerations

Practice sustainability

Inventory decisions: Consider your patient volume, payer mix, and cash flow when deciding whether to stock specialty viscosupplements.

Partnership opportunities: Collaborate with specialty pharmacies or larger practices to ensure patient access without inventory risk.

Patient communication: Develop clear protocols for discussing treatment options, timelines, and costs upfront.

Quality of care maintenance

Don't let availability challenges compromise care quality:

• Maintain expertise across multiple viscosupplement options
• Develop relationships with backup suppliers
• Keep alternative treatment protocols readily available
• Consider referral networks for complex cases

Workflow optimization recommendations

New patient consultation:

1. Assess candidacy for viscosupplementation
2. Check insurance coverage for multiple options
3. Discuss available alternatives upfront
4. Set realistic timeline expectations

Treatment planning:

1. Submit PA for preferred option and backup alternative
2. Confirm inventory or place order after approval
3. Schedule injection appointment with appropriate buffer time
4. Prepare patient for post-injection care protocol

The bottom line for providers

While Synvisc remains an effective treatment option, the 2026 landscape requires more strategic planning than in previous years. Success depends on:

• Understanding your local availability patterns
• Maintaining expertise with multiple viscosupplement options
• Developing efficient PA and inventory processes
• Setting appropriate patient expectations

The goal isn't necessarily to always prescribe Synvisc—it's to ensure patients receive effective viscosupplement therapy without unnecessary delays.

For additional resources on helping patients locate treatments, visit our provider resource center.